Publications by authors named "Michio Sawada"

Claim this Profile
G
Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High-Dose Cytarabine-Based Chemotherapy as Second-Line Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Naoki Hayase, Eri Takada, Michio Sawada

Hematol Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.
Toshiki Yamada, Nobuhiko Nakamura, Hideko Goto, Takeshi Hara, Senji Kasahara, Michio Sawada

Ann Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma.
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Takao Miwa, Eri Takada, Michio Sawada

Hematol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
Nobuhiko Nakamura, Nobuhiro Kanemura, Takuro Matsumoto, Hiroshi Nakamura, Yoshikazu Ikoma, Michio Sawada

Sci Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma.
Nobuhiko Nakamura, Nobuhiro Kanemura, Shin Lee, Kei Fujita, Tetsuji Morishita, Michio Sawada

Leuk Lymphoma· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.
Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada

Exp Hematol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial.
Junichi Kitagawa, Ryo Kobayashi, Yasuyuki Nagata, Senji Kasahara, Takaaki Ono, Michio Sawada

Int J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Takeshi Hara, Takeshi Yoshikawa, Hideko Goto, Michio Sawada, Toshiki Yamada

Hematol Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Takuro Matsumoto, Takeshi Hara, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Michio Sawada

Hematol Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Yuhei Shibata, Takeshi Hara, Senji Kasahara, Toshiki Yamada, Michio Sawada

Hematol Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nobuhiko Nakamura, Naoe Goto, Hisashi Tsurumi, Masao Takemura, Nobuhiro Kanemura, Michio Sawada

Eur J Haematol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Naoe Goto, Hisashi Tsurumi, Masao Takemura, Nobuhiro Kanemura, Senji Kasahara, Michio Sawada

Leuk Lymphoma· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
Hisashi Tsurumi, Takeshi Hara, Naoe Goto, Jun-Ichi Kitagawa, Nobuhiro Kanemura, Michio Sawada

Leuk Lymphoma· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Naoe Goto, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Hara, Michio Sawada

Eur J Haematol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follicular variant of peripheral T-cell lymphoma mimicking follicular lymphoma: a case report with a review of the Literature.
Naoe Goto, Hisashi Tsurumi, Michio Sawada, Nobuhiro Kanemura, Takeshi Hara

Pathol Int· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
Senji Kasahara, Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Jun-Ichi Kitagawa, Michio Sawada

Leuk Lymphoma· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Jun-ichi Kitagawa, Nobuhiro Kanemura, Michio Sawada

J Cancer Res Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Nobuhiro Kanemura, Takeshi Yoshikawa, Michio Sawada

J Cancer Res Clin Oncol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
Jun-ichi Kitagawa, Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Nobuhiro Kanemura, Michio Sawada

J Cancer Res Clin Oncol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Clinical effects of biapenem on febrile neutropenia in patients with hematological malignancy].
Senji Kasahara, Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Nobuhiro Kanemura, Michio Sawada

Jpn J Antibiot· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy.
Nobuhiro Kanemura, Hisashi Tsurumi, Senji Kasahara, Takeshi Hara, Toshiki Yamada, Michio Sawada

Hematol Oncol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma.
Hisashi Tsurumi, Takeshi Hara, Naoe Goto, Nobuhiro Kanemura, Senji Kasahara, Michio Sawada

Hematol Oncol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide.
Hisashi Tsurumi, Nobuhiro Kanemura, Takeshi Hara, Senji Kasahara, Toshiki Yamada, Michio Sawada

J Cancer Res Clin Oncol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Naoe Goto, Hisashi Tsurumi, Masao Takemura, Takeshi Hara, Michio Sawada

Eur J Haematol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
Takeshi Hara, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Yoshikawa, Michio Sawada

Int J Hematol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis